Annual CFF
$16.44 M
+$16.65 M+7975.14%
December 1, 2023
Summary
- As of February 10, 2025, SKYE annual cash flow from financing activities is $16.44 million, with the most recent change of +$16.65 million (+7975.14%) on December 1, 2023.
- During the last 3 years, SKYE annual CFF has risen by +$9.74 million (+145.39%).
- SKYE annual CFF is now at all-time high.
Performance
SKYE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
+$2.10 M+100.00%
September 1, 2024
Summary
- As of February 10, 2025, SKYE quarterly cash flow from financing activities is $0.00, with the most recent change of +$2.10 million (+100.00%) on September 1, 2024.
- Over the past year, SKYE quarterly CFF has dropped by -$85.65 million (-100.00%).
- SKYE quarterly CFF is now -100.00% below its all-time high of $85.65 million, reached on March 1, 2024.
Performance
SKYE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$83.53 M
-$16.63 M-16.61%
September 1, 2024
Summary
- As of February 10, 2025, SKYE TTM cash flow from financing activities is $83.53 million, with the most recent change of -$16.63 million (-16.61%) on September 1, 2024.
- Over the past year, SKYE TTM CFF has dropped by -$18.61 million (-18.22%).
- SKYE TTM CFF is now -18.22% below its all-time high of $102.14 million, reached on March 1, 2024.
Performance
SKYE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
SKYE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7975.1% | -100.0% | -18.2% |
| 3 y3 years | +145.4% | +100.0% | +10000.0% |
| 5 y5 years | +196.8% | +100.0% | +10000.0% |
SKYE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +7975.1% | -100.0% | +100.0% | -18.2% | >+9999.0% |
| 5 y | 5-year | at high | +7975.1% | -100.0% | +100.0% | -18.2% | >+9999.0% |
| alltime | all time | at high | +7975.1% | -100.0% | +100.0% | -18.2% | >+9999.0% |
Skye Bioscience Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $83.53 M(-16.6%) |
| Jun 2024 | - | -$2.10 M(-102.4%) | $100.17 M(-1.9%) |
| Mar 2024 | - | $85.65 M(<-9900.0%) | $102.14 M(+521.2%) |
| Dec 2023 | $16.44 M(-7975.1%) | -$22.70 K(-100.1%) | $16.44 M(-0.3%) |
| Sep 2023 | - | $16.63 M(<-9900.0%) | $16.50 M(-7391.3%) |
| Jun 2023 | - | -$123.40 K(+172.4%) | -$226.30 K(+16.2%) |
| Mar 2023 | - | -$45.30 K(-232.5%) | -$194.70 K(-6.7%) |
| Dec 2022 | -$208.80 K(-101.6%) | $34.20 K(-137.3%) | -$208.70 K(-36.1%) |
| Sep 2022 | - | -$91.80 K(0.0%) | -$326.60 K(-104.5%) |
| Jun 2022 | - | -$91.80 K(+54.8%) | $7.18 M(-20.0%) |
| Mar 2022 | - | -$59.30 K(-29.2%) | $8.98 M(-31.4%) |
| Dec 2021 | $13.08 M(+95.2%) | -$83.70 K(-101.1%) | $13.08 M(-0.9%) |
| Sep 2021 | - | $7.42 M(+335.0%) | $13.20 M(+11.1%) |
| Jun 2021 | - | $1.70 M(-57.8%) | $11.88 M(+10.6%) |
| Mar 2021 | - | $4.04 M(>+9900.0%) | $10.74 M(+60.3%) |
| Dec 2020 | $6.70 M(+11.6%) | $38.00 K(-99.4%) | $6.70 M(-22.8%) |
| Sep 2020 | - | $6.10 M(+975.7%) | $8.68 M(+236.2%) |
| Jun 2020 | - | $566.70 K(>+9900.0%) | $2.58 M(+28.1%) |
| Mar 2020 | - | $0.00(-100.0%) | $2.01 M(-66.5%) |
| Dec 2019 | $6.00 M(+8.4%) | $2.01 M(>+9900.0%) | $6.00 M(+3.5%) |
| Sep 2019 | - | $0.00(0.0%) | $5.80 M(0.0%) |
| Jun 2019 | - | $0.00(-100.0%) | $5.80 M(+0.1%) |
| Mar 2019 | - | $3.99 M(+120.6%) | $5.79 M(+4.5%) |
| Dec 2018 | $5.54 M | $1.81 M(>+9900.0%) | $5.54 M(-9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | $0.00(-100.0%) | $6.11 M(0.0%) |
| Jun 2018 | - | -$7800.00(-100.2%) | $6.11 M(-0.1%) |
| Mar 2018 | - | $3.74 M(+57.1%) | $6.12 M(+74.2%) |
| Dec 2017 | $3.51 M(+761.7%) | $2.38 M(>+9900.0%) | $3.51 M(+128.2%) |
| Sep 2017 | - | $0.00(0.0%) | $1.54 M(0.0%) |
| Jun 2017 | - | $0.00(-100.0%) | $1.54 M(0.0%) |
| Mar 2017 | - | $1.13 M(+177.6%) | $1.54 M(+277.6%) |
| Dec 2016 | $407.70 K(-94.0%) | $407.70 K(>+9900.0%) | $407.70 K(-5260.8%) |
| Sep 2016 | - | $0.00(0.0%) | -$7900.00(-100.2%) |
| Jun 2016 | - | $0.00(0.0%) | $5.03 M(-16.5%) |
| Mar 2016 | - | $0.00(-100.0%) | $6.02 M(-10.7%) |
| Dec 2015 | $6.74 M(+239.6%) | -$7900.00(-100.2%) | $6.74 M(-0.1%) |
| Sep 2015 | - | $5.04 M(+407.7%) | $6.75 M(+294.1%) |
| Jun 2015 | - | $992.30 K(+37.6%) | $1.71 M(+122.4%) |
| Mar 2015 | - | $721.10 K(+1365.7%) | $770.30 K(+975.8%) |
| Dec 2014 | $1.99 M(+2432.9%) | - | - |
| Jul 2014 | - | $49.20 K(>+9900.0%) | $71.60 K(+575.5%) |
| Apr 2014 | - | $200.00(-112.5%) | $10.60 K(-47.0%) |
| Jan 2014 | - | -$1600.00(-106.7%) | $20.00 K(-74.5%) |
| Oct 2013 | $78.40 K(+639.6%) | $23.80 K(-301.7%) | $78.40 K(+43.6%) |
| Jul 2013 | - | -$11.80 K(-222.9%) | $54.60 K(-17.8%) |
| Apr 2013 | - | $9600.00(-83.1%) | $66.40 K(+16.9%) |
| Jan 2013 | - | $56.80 K | $56.80 K |
| Oct 2012 | $10.60 K | - | - |
FAQ
- What is Skye Bioscience annual cash flow from financing activities?
- What is the all time high annual CFF for Skye Bioscience?
- What is Skye Bioscience annual CFF year-on-year change?
- What is Skye Bioscience quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Skye Bioscience?
- What is Skye Bioscience quarterly CFF year-on-year change?
- What is Skye Bioscience TTM cash flow from financing activities?
- What is the all time high TTM CFF for Skye Bioscience?
- What is Skye Bioscience TTM CFF year-on-year change?
What is Skye Bioscience annual cash flow from financing activities?
The current annual CFF of SKYE is $16.44 M
What is the all time high annual CFF for Skye Bioscience?
Skye Bioscience all-time high annual cash flow from financing activities is $16.44 M
What is Skye Bioscience annual CFF year-on-year change?
Over the past year, SKYE annual cash flow from financing activities has changed by +$16.65 M (+7975.14%)
What is Skye Bioscience quarterly cash flow from financing activities?
The current quarterly CFF of SKYE is $0.00
What is the all time high quarterly CFF for Skye Bioscience?
Skye Bioscience all-time high quarterly cash flow from financing activities is $85.65 M
What is Skye Bioscience quarterly CFF year-on-year change?
Over the past year, SKYE quarterly cash flow from financing activities has changed by -$85.65 M (-100.00%)
What is Skye Bioscience TTM cash flow from financing activities?
The current TTM CFF of SKYE is $83.53 M
What is the all time high TTM CFF for Skye Bioscience?
Skye Bioscience all-time high TTM cash flow from financing activities is $102.14 M
What is Skye Bioscience TTM CFF year-on-year change?
Over the past year, SKYE TTM cash flow from financing activities has changed by -$18.61 M (-18.22%)